In November 2024, China Merchants Group's strategic equity investment in Cathay Biotech through private placement received approval and registration from the China Securities Regulatory Commission (CSRC), thus joining the top tier in China's biomanufacturing sector. CMIT has carried out in-depth cooperation with Cathay Biotech and the Hefei Municipal Government, and through strategic initiatives such as investment and equity participation, it is gradually completing the puzzle of its industrial layout.